Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R

ABSTRACT

This invention provides a method for regulating migration of neuronal progenitor cells in the nervous system of a mammal. The method comprises providing a mammal with TNR, a biologically active fragment of TNR, or a TNR agonist in an amount sufficient to direct migration of the neuronal progenitor cells. The invention provides a method of treating neurological diseases by replenishing diseased, damaged, or destroyed neural cells in the central nervous system or in the peripheral nervous system.

This is a division of application Ser. No. 11/078,479, filed Mar. 14, 2005, now U.S. Pat. No. 7,432,251, which is incorporated herein by reference.

FIELD OF THE INVENTION

This invention relates to the use of tenascin-R (TNR) to modulate migration of neural cells in the central nervous system (CNS) or peripheral nervous system (PNS). More particularly, this invention relates to methods of exposing a patient suffering from a disorder of the nervous system to TNR and achieving regulation of neuronal precursor migration in the patient's CNS or PNS to reduce at least one symptom of the disorder.

BACKGROUND OF THE INVENTION

The olfactory bulb (OB) is one of the few structures in the adult forebrain in which there is a continuous supply of newborn neurons (Luskin, 1993; Alvarez-Buylla, et al., 2002). The neural progenitors, which originate from stem cells located in the subventricular zone (SVZ) of the lateral ventricles, follow an intricate path of migration before reaching their final position in the OB. First, they migrate tangentially, in chains, along the entire extent of the rostral migratory stream (RMS), and once in the bulb, turn to migrate radially out of the RMS into the outer layers, where they differentiate into inhibitory interneurons (Luskin, 1993; Alvarez-Buylla, et al., 2002).

Despite increasing knowledge on the origin, proliferation, and tangential migration of neuroblasts, the way by which they achieve their radial migration to functionally integrate into the bulbar circuitry remains elusive. Interestingly, radial glia, which are central for axonal guidance and radial migration during development, are no more present in the adult OB (Alvarez-Buylla, et al., 2002). This implies that neuroblasts arriving in the rostral extension of the RMS of adult forebrain follow unique migratory pathways, quite distinct from those observed at perinatal stages. Although a recent report has provided evidence that the OB-derived extracellular matrix (ECM) molecule reelin affects detachment of neuroblasts from chains, once they have reached the OB (Hack, et al., 2002), the identity of the cues halting tangential migration, initiating detachment of neuroblasts from the RMS and facilitating their radial migration have yet to be characterized. Furthermore, the impact of sensory experience in these processes needs to be examined.

The ability to generate neurons in the adult brain is relevant to the development of therapeutic strategies aimed at directing the migration and individualization of endogenous and/or grafted progenitor cells. Recently, it has been demonstrated that endogenous adult stem cells have the ability to regenerate functional neurons in non-neurogenic diseased areas (Magavi et al., 2000; Arvidsson, et al., 2002; Nakatomi, et al., 2002). Neuronal progenitors migrate to the damaged areas from the neurogenic source localized in the SVZ suggesting that not only increased proliferative activity following brain damage (Arvidsson, et al., 2002; Nakatomi, et al., 2002), but also changes either in the migratory capabilities of neuroblasts and/or in the microenvironment of the target tissues may help to recruit the newly generated neurons for repair. According to this invention, recruitment of neuronal progenitors in diseased areas of the nervous system can be considerably enhanced by application of TNR.

A better understanding of neural migration provides the basis for new treatments for neurological disease and damage, which are needed in the art. This invention aids in fulfilling this need.

SUMMARY OF THE INVENTION

This invention resulted from an investigation of the possibility that reoriented migration of neuroblasts in the core of the OB is orchestrated by a gradient of extracellular cues surrounding the RMS within the OB. It was discovered that the expression pattern of the ECM molecule tenascin-R (TNR) would be compatible with such a functional role: mice lacking a functional TNR gene demonstrate an accumulation of neuroblasts in the RMS_(OB), indicating a defect of radial migration in the OB. Furthermore, in vivo and in vitro, neuroblasts migrate towards cells that have been engineered to express TNR. Thus, this invention relies on the ability of TNR to modulate the migration of neuroblasts.

More particularly, this invention provides a method for regulating migration of endogenous or exogenous newborn neuronal cells in the central nervous system or peripheral nervous system of a mammal suffering from a disease or damage to alleviate a symptom or symptoms of the disease or damage by administering TNR to the mammal. Administration of TNR in the extracellular space of a damaged or diseased central nervous system or peripheral nervous system tissue can induce endogenous or grafted neural progenitor cells to migrate towards this site for tissue repair by cell replacement or by creating a better microenvironment for already existing cells.

The invention also provides for a method of treating a neurological disease by regulating migration of neural cells in the central or peripheral nervous system by administering a composition comprising TNR, or a fragment, derivative, or analog of TNR, and inducing the neuronal cells to migrate to the region of disease or damage.

Furthermore, the invention provides a pharmaceutical composition for treating neurological disease, which comprises TNR, a fragment, derivative, or analog of TNR, and a pharmaceutically acceptable carrier. In aspects of the invention, this pharmaceutical composition enhances the permeability of the ventricle wall.

In another aspect, the invention provides a screening test for a molecule that regulates neuronal cell migration by administering a candidate molecule to a TNR-deficient mouse, observing neuronal cell migration, and comparing neuronal cell migration to migration in a non-treated TNR-deficient mouse. A difference in the neuronal cell migration between the treated and non-treated mice indicates that the molecule regulates neuronal cell migration.

BRIEF DESCRIPTION OF THE DRAWINGS

The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawings will be provided by the Office upon request and payment of the necessary fee.

This invention will be described in detail with reference to the drawings in which:

FIGS. 1A-C: cDNA sequence of human TNR (SEQ ID NO: 1).

FIG. 2: Amino acid sequence of human TNR (SEQ ID NO: 2).

FIG. 3: Immunohistological detection of TNR in the SVZ-OB pathway of adult mice. Sagittal sections of (a) SVZ and (b) RMS immunostained for TNR (red) and PSA-NCAM (green). (c) Coronal section of OB stained for TNR (left panels) and PSA-NCAM (right panels). Note the absence of staining for TNR in the SVZ, RMS and RMS_(OB), but presence in the GCL and IPL. (d) High magnification images of TNR and PSA-NCAM staining in the OB. Scale bars: a and b, 50 μm; c, 200 μm; d, 100 μm. CC, corpus callosum; EPL, external plexiform layer; IPL, internal plexiform layer; LV, lateral ventricle; RMS_(OB), rostral migratory stream of the olfactory bulb; ST, striatum; SVZ, subventricular zone.

FIG. 4: Reduced density of newborn cells in the OB of TNR-deficient mice, 21 days following BrdU injection. Quantification of BrdU+ nuclei in the GCL (a) and GL (c) of control (left panels) and TNR-deficient (right panels) mice reveals a pronounced reduction in the number of newborn cells in the mutant. Mean densities of newborn granule (b) and periglomerular (d) cells in control (+/+) and TNR-deficient (−/−) mice. **, P<0.01. (e) Confocal 3D reconstruction of BrdU+ cells (red) in control (left panel) and TNR-deficient (right panel) mice stained for the neuronal marker NeuN (green). Reconstructed orthogonal projections are presented as viewed in the x-z (top) and y-z (right) planes. (f) Percentage of BrdU+ cells double-labeled with NeuN in control (+/+) and TNR-deficient (−/−) mice. (g) Double immunostaining for BrdU (red) and the astrocytic marker GFAP (green) in the gcl of control (left panel) and TNR-deficient (right panel) mice. (h) Percentage of BrdU+ cells double-labeled with GFAP in control and TNR-deficient mice. In total, 940 (from 3 control animals) and 972 (from 4 TNR-deficient mice) randomly chosen BrdU+ cells were inspected for NeuN immunostaining. Similarly, 836 and 1292 BrdU+ cells were checked for GFAP immunopositivity. GCL, granule cell layer; GL, glomerular layer. Scale bars: a and c, 100 μm; e, 10 μm; g, 50 μm. Values in histograms are means±SEM.

FIG. 5: Normal proliferation in the SVZ and RMS of TNR-deficient mice. (a) BrdU immunostaining in sagittal sections through the forebrain of control (+/+, left panels) and TNR-deficient (−/−, right panels) mice showing the distribution of BrdU+ cells in the SVZ-RMS pathway. High magnification images of the SVZ (b) and RMS (c) indicate similar numbers of mitotically active cells. (d) Quantification of BrdU+ nuclei in the SVZ and the RMS in control (+/+) and TNR-deficient (−/−) mice. Data are presented as means±SEM. Scale bars: a, 500 μm; b and c, 100 μm.

FIG. 6: Normal chain organization and tangential migration of neuroblasts in TNR-deficient mice. (a) Whole-mount immunostaining of PSA-NCAM+ chains in the SVZ of control (+/+, left panels) and TNR-deficient (−/−, right panels) mice. Insets show a high magnification of the PSA-NCAM+ network of chains. PSA-NCAM (green) and BrdU (red) immunostaining in the RMS of control (left panel) and TNR-deficient (right panel) mice at low (b) and high (c) magnifications. (d) Phase-contrast images of SVZ explants of control (left panel) and TNR-deficient (right panel) mice cultured in Matrigel for 20 hours. (e) High magnification images of boxed areas in (d) showing chain organization of neuroblasts migrating out of the SVZ explants. (f) Quantification of migration distance revealed no difference between control (+/+) and TNR-deficient (−/−) explants. Data are presented as means±SEM. Scale bars: a, 100 μm and inset, 40 μm; b and d, 100 μm; c, 30 μm; e, 40 μm.

FIG. 7: Abnormal radial migration in the OB of TNR-deficient mice. (a) TUNEL+ nuclei (arrows) in the GCL of control (+/+) and mutant (−/−) mice. (b) Quantification of TUNEL+ nuclei in the GCL and the RMS_(OB) of control and TNR-deficient mice reveals no significant differences in the number of apoptotic cells. (c) BrdU immunostaining in coronal sections of control (left panel) and TNR-deficient (right panel) mice 2 days after BrdU injection. Note the higher density of BrdU+ nuclei in the RMS_(OB) of TNR-deficient mice. (d) Quantification of BrdU+ nuclei in coronal sections from RMS_(OB) to SVZ (120 μm bin size) in control (black squares) and TNR-deficient (grey circles) mice indicates a significant increase in the density of newborn cells exclusively in the RMS_(OB) of TNR-deficient mice. (e) Conversely, a reduced number of newborn cells is seen in the OB of TNR-deficient mice. (f) The total number of BrdU+ nuclei in the OB, excluding the RMS_(OB), is 53±7 versus 38±5 BrdU+ cells/mm², in control and TNR-deficient mice, respectively. (g) Time-dependent accumulation of neuroblasts in the RMS_(OB) of TNR-deficient as compared to control mice four hours and two days following BrdU injection. (h) Significant increase in the ratio of BrdU+ cells in the RMS_(OB) of TNR-deficient versus control mice measured two days as compared to four hours after BrdU injection. Data are derived by normalizing individual values of TNR-deficient mice to the mean values of controls at each time point. Data are presented as means±SEM. * and ** indicate significant differences of P<0.05 and P<0.01, respectively. Scale bars: a 50 μm; c and e, 100 μm.

FIG. 8: TNR acts as a detachment signal for tangentially migrating neuroblasts. (a) PSA-NCAM immunostaining in coronal sections of the gcl of control (+/+, left panel) and TNR-deficient (−/−, right panel) mice show that PSA-NCAM+ cells migrate individually (arrows) in control mice, whereas they appear clustered (arrowheads) in TNR-deficient mice. (b) Phase-contrast image showing co-cultures of SVZ explants (left) with an aggregate of BHK cells (right). Examples of SVZ explants co-cultured with BHK cells not secreting (c) and secreting (d) TNR. Right panels are higher magnifications of boxed areas in left panels. Note the increased number of individualized cells in co-cultures of SVZ explants with BHK cells secreting TNR. (e) Significant increase in the number of individualized cells in co-cultures of SVZ explants with BHK cells secreting TNR (41.5±5.8 versus 77±5.9). **, P<0.001. (f) Quantification of migration distance of neuroblasts from SVZ explants co-cultured with BHK cells not secreting (Ctrl) or secreting (TNR) TNR. Data are presented as means±SEM. Twenty-one and 27 explants from seven animals were analyzed in cultures without and with TNR, respectively. Scale bars: a and d_(right), 50 μm; b and d_(left), 100 μm.

FIG. 9: Ectopic expression of TNR de-routes migrating neuroblasts. (a) BrdU immunostained sagittal section showing the place of BHK cells grafts (red circles). (b) Control (upper panels, Ctrl) or TNR-secreting (lower panels, TNR) BHK cells pre-labeled with PKH26 (red staining) were placed into the striatum neighboring the SVZ. The de-routed neuroblasts were quantified by counting PSA-NCAM+ cells (green staining) in the 400 μm diameter area calculated from the perimeter of the graft. Note the TNR immunopositive areas (blue staining) in animals injected with BHK cells secreting TNR (lower panels). (c) Same as in (b), but control and TNR-transfected BHK cells were grafted into the area just above the horizontal limb of the RMS (hIRMS). Right panels show high magnifications of the boxed areas shown on the left. Arrowheads indicate chains of neuroblasts de-routed from the SVZ (b) or RMS (c). High magnification images of striatum (d) and area just above the hIRMS (f) injected with BHK cells secreting TNR. Arrows and arrowheads indicate, respectively, the individual neuroblasts and chains of progenitor cells de-routed from their normal migratory pathway. (e, g) Quantification of the number of neuroblasts de-routed from the SVZ (e) and RMS (g) by non-transfected (Ctrl) and TNR-transfected BHK cells (TNR). **, P<0.001. Scale bars: b and c, 200 and 50 μm for left and right panels, respectively; d and f, 20 μm.

FIG. 10: Activity-dependent expression of TNR in the OB. (a) Pseudocolor images showing expression of TNR mRNA in a coronal section through the OB receiving inputs from nostrils that had been open (Ctrl) or closed (Occl) for 10 days. The images were obtained by β-imager with the exposure time of 20 hours. Note the decreased expression of TNR mRNA in the odor-deprived OB. (b) The effect of sensory deprivation on TNR mRNA expression was calculated by relating the mean radioactivity (in cpm/mm²) of occluded bulb to that of control one. The measurements were performed at least from 20-30 coronal sections per animals and they were two to three animals per group. (c) TNR immunostaining of a coronal section through the OB receiving inputs from open (Ctrl) and closed (Occl) nostrils, 20 days following unilateral odor deprivation. Note decreased immunostaining for TNR in the GCL of the odor-deprived bulb. (d) The ratio of mean fluorescent intensity (per mm²) in the GCL of occluded bulb to that of control bulb in TNR immunostained sections (n=6 animals). (e) BrdU+ cells in the RMS_(OB) of control and occluded bulbs two days following BrdU injection. Unilateral sensory deprivation was performed 30 days before BrdU injection. The sections were counterstained with methyl green and arrowheads indicate BrdU+ cells in the GCL. (f) Quantification of BrdU+ nuclei in the RMS_(OB) of control (Ctrl) and occluded (Occl) bulbs indicates a significant increase in the density of newborn cells following sensory deprivation. * and ** indicate significant differences of P<0.05 and P<0.01, respectively. Scale bars: c, 200 μm and e, 50 μm.

FIG. 11: Normal proliferation in the RMS_(OB) of TNR-deficient mice. (a) PSA-NCAM (green) and BrdU (red) immunostaining in the RMS_(OB) of control and TNR-deficient mice two hours following BrdU injection. Note the very low numbers of BrdU+ cells (arrows) in the two groups. (b) Quantification of BrdU+ cells two hours following BrdU injection and the proliferative marker Ki67+ cells in the RMS_(OB) of control and TNR-deficient mice reveal no difference in the proliferation rates between the two genotypes. Data are presented as means±SEM. Scale bars: a, 50 μm.

DETAILED DESCRIPTION OF THE INVENTION

Neuroblasts born in the adult forebrain that travel to the olfactory bulb (OB) use two modes of migration: tangentially, along the rostral migratory stream, and radially, in the core of the OB where they start to ascend to the outer layers. While the mechanisms of tangential migration have been extensively studied, the factors controlling radial migration remain unexplored.

TNR is a member of the tenascin gene family and is composed of cysteine-rich amino terminal region, epidermal growth factor-like domains, fibronectin-type III homologous repeats, and a domain homologous to fibrinogen (Jones and Jones, 2000). TNR appears to be restricted to the CNS and is expressed by differentiating oligodendrocytes and some inhibitory interneurons at late embryonic stages (Jones and Jones, 2000; Fuss, et al., 1993). The functions of TNR are manifold: TNR binds to voltage-dependent Na⁺-channels (Srinivasan, et al., 1998; Xiao et al., 1999) and conductance velocity of action potential is reduced in TNR-deficient mice (Weber, et al., 1999). Also, TNR is an important constituent of perineuronal nets surrounding many, but not all, inhibitory interneurons (Bruckner, et al., 2000) and organization of perineuronal nets is perturbed in TNR-deficient mice. Additionally, it has been shown that TNR-deficient mice display alterations in the organization of symmetric, presumably inhibitory, perisomatic synapses (Nikonenko, et al., 2003) as well as synaptic transmission and plasticity in the CA1 region of hippocampus (Saghatelyan, et al., 2001).

It has now been discovered that TNR, expressed in the adult mouse OB, initiates both the detachment of neuroblasts from chains and their radial migration. Expression of TNR is neuronal activity-dependent, since it is drastically reduced by odor deprivation. Furthermore, grafting of TNR-transfected cells into non-neurogenic regions de-routes migrating neuroblasts toward these regions. The identification of an extracellular microenvironment capable of directing migrating neuroblasts provides insights into the mechanisms regulating radial migration away from the RMS into the outer layer of the adult OB, thus offering a promising tool for cell replacement therapies.

It has been shown that TNR can enhance or decrease neurite outgrowth and neuronal adhesion depending on the cell type and association of TNR with other ECM molecules (Pesheva and Probstmeier, 2000). Furthermore, TNR has been found to defasciculate axons of cerebellar granule cells in vitro, thus possibly allowing inhibitory interneurons to invade the tightly fasciculating bundles of axonal processes (Xiao et al., 1998). These observations are pertinent in view of the fact that TNR induces detachment of neuroblasts from chains in the core of OB and initiates their radial migration into the outer layers. Similarly, reelin has been reported to influence this process in the adult OB (Hack et al., 2002). TNR and reelin could share the same signaling pathway to induce detachment of neuroblasts from chains. Therefore, the effect on SVZ explants of transfected cells expressing TNR may be comparable with that obtained in presence of transfected cells expressing TNR and reelin. Nevertheless, while reelin affects only detachment of neuroblasts (Hack, et al., 2002), TNR also acts as a directional cue that de-routes neuronal progenitors from their tangential migratory pathway. These results indicate that either TNR activates two independent pathways used separately for neuroblasts detachment and their radial reorientation (the former might be also used by reelin), or it acts via a unique pathway that is different from that used by reelin.

TNR can act directly by interacting with particular cellular receptors present on migrating neuroblasts, or indirectly, together with other ECM associated molecules, by capturing and presenting some growth factors (Boudreau and Bissell, 1998) necessary for radial migration. Among cell surface receptors for TNR are contactin/F3 (Pesheva et al., 1993), acetylated gangliosides that influence phosphorylation of focal adhesion kinases and affect integrin function (Probstmeier, et al., 1999) and receptor protein-tyrosine phosphatases belonging to the family of chondroitin sulfate proteoglycans (CSPGs) (Xiao, et al., 1997; Milev, et al., 1998). While the involvements of contactin/F3 and CSPGs, the latter being highly expressed in the adult RMS (Thomas, et al., 1996), remain to be explored in adult neurogenesis, it has been recently shown that integrins are not involved in the radial migration of neuroblasts to the OB (Murase, et al., 2002). Interestingly, initiation of radial migration in the adult OB correlates with the appearance of NMDA receptor (NMDAR)-mediated currents (Carleton, et al., 2003). These receptors are involved in neuronal migration during early developmental stages (Komuro and Rakic, 1993). Thus, TNR, via its cell surface receptor(s), can trigger the expression of functional NMDARs and, as a consequence, radial migration. Alternatively, TNR can also directly interact with NMDARs through a mechanism similar to that described for GABA_(B)Rs (Saghatelyan, et al., 2003), and thus control radial migration more directly. Regardless of the mechanism, TNR plays a specific and important role in the initiation of radial migration of newborn neurons in the adult forebrain.

It is believed that target structures provide attractive and/or survival factors for developing neuronal networks (Kennedy and Tessier-Lavigne, 1995; Svendsen and Sofroniew, 1996) and that these factors can be regulated in an activity-dependent manner. For instance, in the olfactory system, modulation of odor information flow has been reported to affect the survival of newborn neurons: sensory deprivation by nostril occlusion reduces granule cell number in the developing (Frazier and Brunjes, 1998; Brunjes, 1994; Cummings and Brunjes, 1997) and adult OB (Henegar and Maruniak, 1991), whereas re-opening the nostril following early occlusion (Cummings and Brunjes, 1997), as well as olfactory enrichment in adults (Rochefort et al., 2002) increases the number of newly formed bulbar interneurons. Thus, in addition to the reduced survival of newborn neurons following nostril occlusion, odor deprivation also impairs radial migration of neuroblasts from the RMS to the OB, via downregulation of TNR expression, further demonstrating that TNR is an important mediator relaying network activity to the recruitment of newborn neurons into the OB.

As indicated above, the present invention relates to the administration of TNR to modulate the migration of neural cells as a therapy for central nervous system or peripheral nervous system disease, disorder, or damage.

As used herein, the term “modulate” or the term “regulate” refers to having an effect in such a way as to alter the migration of a neural cell, such as, but not limited to a neural stem cell (NSC) or neural progenitor cell, also called neural precursor cells (NPC). As used herein, the term “migrate” refers to movement of a neural cell from one region of the central or peripheral nervous system to another.

NSCs can be identified by their ability to undergo continuous cellular proliferation, to regenerate exact copies of themselves (self-renew), to generate a large number of regional cellular progeny, and to elaborate new cells in response to injury or disease. NPCs mean cells that can generate progeny that are either neuronal cells (such as neuronal precursors or mature neurons) or glial cells (such as glial precursors, mature astrocytes, or mature oligodendrocytes). Typically, the cells express some of the phenotypic markers that are characteristic of the neural lineage. They also do not usually produce progeny of other embryonic germ layers when cultured by themselves in vitro unless dedifferentiated or reprogrammed in some fashion. As used herein, the term “neurosphere” refers to the ball of cells consisting of NSCs and NPCs.

The tenascins are a family of large extracellular matrix glycoproteins that comprise five known members (tenascin-C, tenascin-R (TNR), tenascin-X, tenascin-Y, and tenascin-W). All members of this family, except TN-W, have been shown to occur in multiple isoforms due to alternative splicing. TNR appears in many molecular forms with the predominant ones displaying apparent molecular masses of 220, 200, 180, and 160 kD (Kruse et al., Nature, 316:146-48, 1985).

The human TNR cDNA sequence is provided in FIG. 1. The human TNR amino acid sequence is provided in FIG. 2.

As used herein, the term “administering” refers to any action that results in the presence of TNR in an area where its action on neuronal cell migration is expected. “Administration” can include, but is not limited to, methods of infusion, methods of expressing TNR in cells, for example by gene therapy, or other methods of providing TNR to a region.

In embodiments of the invention, the TNR administered to a patient can be any of the molecular forms of TNR in which TNR naturally occurs or as biologically active fragments of these molecular forms. In a preferred embodiment TNR is 220, 200, 280, or 160 kD. In a more preferred embodiment, the 180 kD TNR is administered.

The invention also pertains to variants of TNR that function as agonists (mimetics). Variants of TNR can be generated by mutagenesis, e.g., discrete point mutations. In contrast, an agonist can retain substantially the same, or a subset of, the biological activities of the naturally occurring protein. An antagonist can inhibit one or more of the activities of naturally occurring protein by, for example, competitively binding to the receptor. Thus, specific biological effects can be elicited by treatment with a variant having a limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of TNR has fewer side effects in a subject relative to treatment with the naturally occurring form of the TNR.

Preferably, the analog, variant, or derivative TNR is functionally active. As utilized herein, the term “functionally active” refers to species displaying one or more known functional attributes of a full-length TNR. A “variant” refers to protein or peptide that differs from naturally occurring TNR, but that retains essential properties thereof.

In one embodiment of the invention, TNR is administered as an isolated, purified protein. This protein can be recombinantly produced, purified, and formulated according to well known methods or it can be chemically synthesized.

In one embodiment, TNR proteins or biologically active peptides of TNR may be synthesized for administration to a patient. A variety of protein synthesis methods are common in the art, including synthesis using a peptide synthesizer. See, e.g., Bodansky, ed., 1988; Merrifield, 1986; Barany, et al., 1987; Kent, 1988; Daiser, et al., 1989.

Chemical synthesis of peptides facilitates the incorporation of modified or unnatural amino acids, including D-amino acids and other small organic molecules. Replacement of one or more L-amino acids in a peptide with the corresponding D-amino acid isoforms can be used to increase the resistance of peptides to enzymatic hydrolysis, and to enhance one or more properties of biologically active peptides, e.g., receptor binding, functional potency or duration of action. In addition, the introduction of covalent cross-links into a peptide sequence can conformationally and topographically constrain the peptide backbone. This strategy can be used to develop peptide analogs of TNR, or fragments, derivatives, or analogs thereof, with increased potency, selectivity, and stability.

In an alternative embodiment, TNR or a biologically active fragment of TNR may be obtained by methods well-known in the art for recombinant peptide expression and purification using the known sequence of the TNR cDNA. Optionally, the nucleic acid molecule reciting this sequence or a fragment of it can include additional sequences, for example, but not limited to restriction enzyme recognition sites that facilitate cloning into a suitable cloning vector, such as a plasmid. The nucleic acid may be DNA, RNA, or a combination thereof. Nucleic acids encoding the TNR, or fragments, derivatives, or analogs thereof, may be obtained by any method known within the art (e.g., by PCR amplification using synthetic primers hybridizable to the 3′- and 5′-termini of the sequence and/or by cloning from a cDNA or genomic library using an oligonucleotide sequence specific for the given gene sequence, or the like). Alternatively, nucleic acids can also be generated by chemical synthesis.

In another embodiment of the invention, any of the methodologies known for the insertion of nucleic acid fragments into a vector may be used to construct expression vectors that contain a chimeric gene comprised of the appropriate transcriptional/translational control signals and TNR-coding sequences. Promoter/enhancer sequences within expression vectors may use regulatory sequences from organisms such as, but not limited to, plants, animals, insects, or fungi.

A host cell for the expression of TNR or biologically active fragments of TNR can be any prokaryotic or eukaryotic cell. For example, the protein or peptide can be expressed in bacterial cells, including, but not limited to, E. coli, insect cells, fungi or mammalian cells (such as Chinese hamster ovary cells (CHO), baby hamster kidney cells (BHK cells), or COS cells). Other suitable host cells are known to those skilled in the art. In one embodiment, a nucleic acid encoding a TNR, or a fragment, derivative, or analog thereof, is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987) and pMT2PC (Kaufman et al., 1987).

The host cells can be used to produce (e.g., overexpress) peptide in culture. Accordingly, the invention further provides methods for producing the TNR protein or biologically active fragments of TNR using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding the peptide has been introduced) in a suitable medium such that protein or peptide is produced. The method further involves isolating peptide from the medium or the host cell. (Ausubel et al., 1998)

An “isolated” or “purified” recombinant peptide or biologically active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the peptide of interest is derived. The language “substantially free of cellular material” includes preparations in which the peptide is separated from cellular components of the cells from which it is isolated or recombinantly produced. In one embodiment, the language “substantially free of cellular material” includes preparations of peptide having less than about 30% (by dry weight) of peptide (also referred to herein as a “contaminating protein”) other than the desired peptide, more preferably less than about 20% of contaminating protein, still more preferably less than about 10% of contaminating protein, and most preferably less than about 5% contaminating protein. When the peptide or biologically active portion thereof is recombinantly produced, it is also preferably substantially free of culture medium, e.g., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the peptide preparation.

Variants of TNR that function as either agonists (mimetics) or as antagonists can be identified by screening libraries of mutants of TNR for agonist or antagonist activity. In one embodiment, a variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential sequences is expressible as individual peptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of sequences therein. There are a variety of methods that can be used to produce libraries of potential variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential sequences. Methods for synthesizing degenerate oligonucleotides are known in the art. See, e.g., Narang, 1983; Itakura et al., 1984a; Itakura et al., 1984b; Ike et al., 1983.

Derivatives and analogs of TNR or individual moieties can be produced by various methods known within the art. For example, the polypeptide sequences may be modified by any number of methods known within the art. See e.g., Sambrook, et al., 1990. Modifications include: glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, linkage to an antibody molecule or other cellular reagent, and the like. Any of the numerous chemical modification methodologies known within the art may be utilized including, but not limited to, specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH₄, acetylation, formylation, oxidation, reduction, metabolic synthesis in the presence of tunicamycin, etc.

Derivatives and analogs may be full length or other than full length, if said derivative or analog contains a modified nucleic acid or amino acid, as described infra. Derivatives or analogs of the TNR include, but are not limited to, molecules comprising regions that are substantially homologous in various embodiments, of at least 30%, 40%, 50%, 60%, 70%, 80%, 90% or preferably 95% amino acid identity when: (i) compared to an amino acid sequence of identical size; (ii) compared to an aligned sequence in that the alignment is done by a computer homology program known within the art (e.g., Wisconsin GCG software) or (iii) the encoding nucleic acid is capable of hybridizing to a sequence encoding the aforementioned peptides under stringent (preferred), moderately stringent, or non-stringent conditions. See, e.g., Ausubel, et al., 1993.

Derivatives of TNR may be produced by alteration of its sequence by substitutions, additions, or deletions that result in functionally-equivalent molecules. One or more amino acid residues within TNR may be substituted by another amino acid of a similar polarity and net charge, thus resulting in a silent alteration. Conservative substitutes for an amino acid within the sequence may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan and methionine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine. Positively charged (basic) amino acids include arginine, lysine and histidine. Negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

As an alternative to administering TNR as a purified, isolated protein or peptide, the invention provides for the administration of TNR, a functionally active fragment of TNR, a derivative of TNR, or an analog of TNR as a protein or peptide expressed from a recombinant cell introduced into the patient's central or peripheral nervous system. In this embodiment, the nucleotides encoding TNR, or a fragment, derivative, or analog of TNR, can be inserted into the mammalian cells using any in vitro nucleotide transfer procedure.

The invention encompasses using several different cell types to express TNR, a fragment of TNR, a derivative of TNR, or an analog of TNR. These include, but are not limited to, all glial cell types, neuronal embryo cells, and neuronal stem cells. Preferably, these cells expressing TNR, or a fragment, derivative or analog thereof, are derived from the same patient into whom the cells are to be administered.

In vitro gene transfer can be carrier out by, for example, but not limited to, chemical methods, such as calcium phosphate mediated transfection; physical methods, such as electroporation, microinjection, and particle bombardment; fusion methods, such as by the use of liposomes; receptor-mediated endocytosis; and recombinant viruses, such as adenovirus, adeno-associated virus (AAV), herpes simplex virus, human immunodeficiency virus, maloney murine leukemia virus, and vaccinia virus.

It will be understood that replication defective viruses can be used as gene transfer vectors. Defective replication means that such viruses are not infectious in the absence of a helper virus that can supply missing viral genes to complete the viral life cycle. A helper cell line that contains integrated provirus sequences that supply viral structural proteins can be employed for this purpose.

When a retroviral vector is employed for gene transfer, the retroviral vector can be constructed by discarding the protein coding sequences of the retroviral genome (gag, pot, and env), and replacing by heterologous coding sequences, while retaining essential cis-acting elements. These essential elements include a packaging signal sequence that ensures the encapsidation of the vector RNA into virions (Psi in murine vectors or E in avian systems); elements that are necessary to direct the process of reverse transcription, such as the primer binding site (PBS), which binds the tRNA primer of reverse transcription, terminal repeat (R) sequences that guide the reverse transcriptase between RNA strands during DNA synthesis; a purine-rich sequence 5′ of the 3′ LTR that serves as the priming site for synthesis of the second (plus) DNA strand; and specific sequences near the ends of the LTRs that are necessary for integration of the vector DNA into the host cell chromosome in the ordered and reproducible manner characteristic of retroviruses.

A retroviral packaging cell line can be employed to provide the viral helper functions, which have been deleted from the vector genome, namely the gag, pol, and env proteins. These helper functions should be stably expressed in the packaging cells from one or more helper plasmids whose RNA transcripts are not efficiently packaged into viral particles because they lack the packaging signal sequence. When a vector genome is transfected into such packaging cells, the viral gag proteins recognize and package the vector RNA genome into viral particles, which are released into the culture supernatant. Viral particles can be collected from the supernatants.

Other vectors can be used besides retroviral vectors, including those derived from DNA viruses, such as simian virus (SV40), bovine papilloma viruses, and also polyoma and herpes viruses. The cells can be expanded in number before or after insertion of the nucleotides encoding TNR, or a fragment, a derivative, or an analog thereof, independent of the method employed to transfer the nucleotides to the mammalian somatic cell.

The marker nucleotides can be any nucleotides encoding TNR or other marker nucleotides. Examples of such marker nucleotides include neoR, multi-drug resistant nucleotides, thymidine kinase nucleotides, beta-galactosidase, dihydrofolate reductase (DHFR), and chloroamphenicol acetyl transferase. The marker nucleotides can be inserted into a mammalian cell together with nucleotides encoding TNR, or a fragment, derivative, or analog thereof, or separately. The marker nucleotides and the therapeutic nucleotides can also be one and the same, namely, nucleotides encoding TNR, or a fragment, derivative, or analog thereof. Dual gene constructs in which one of the genes encodes an antibiotic resistance marker offer the advantage that the TNR-transduced target cells in a culture can be selected from a background of non-transduced cells.

Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Pat. No. 5,328,470) or by stereotactic injection (see e.g., Chen et al., 1994). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.

The procedure is performed in such a manner that upon transfer into the host, the cells will produce the TNR, or a fragment, derivative, or analog thereof, in the host, preferably at the site of administration or proximate thereto. The TNR, or a fragment, derivative, or analog thereof, should be produced in an amount sufficient and under conditions that modulate a biological function in the recipient. Thus, for example, in the case of a neurological disorder, the cells containing nucleotides encoding the TNR, TNR fragment, TNR derivative, or TNR analog, should be transplanted into a neurological site, such as the brain, and expressed TNR should be secreted from the cells into extracellular medium in sufficient amounts to affect neurological function. Short-term expression of TNR at basal levels in the recipient is generally adequate.

In embodiments of the invention, TNR, a biologically active fragment of TNR, a derivative of TNR, or an analog of TNR can be administered locally to any loci implicated in the CNS disorder pathology, e.g. any loci where (or close to the place where) neural cells are suffering. Attracted newborn cells can repair the damaged tissue or alternatively can produce survival factors that will reduce neuronal cell death. For example, TNR, a biologically active fragment of TNR, or an agonist of TNR can be administered locally to the sites including, but not limited to, the volume adjacent to the lateral wall, the hippocampus, alveus, ventricle of the brain, substantia nigra, striatum, locus ceruleous, nucleus basalis of Meynert, pedunculopontine nucleus, cerebral cortex, spinal cord and retina, or any region of tissue that is impaired by stroke injury, ischemic injury, or injury due to any disease.

In embodiments of the invention, TNR, a biologically active form of TNR, or a TNR agonist is administered in an amount of 0.001 ng/kg/day to 10 mg/kg/day, preferably in an amount of 0.01 ng/kg/day to 5 mg/kg/day, more preferably in an amount of 0.1 ng/kg/day to 1 mg/kg/day and most preferably in an amount of 0.1 ng/kg/day to 1 μg/kg/day, in a volume of 0.0001 to 10 ml. The administration can be local or systemic and can optionally be in a combination with a ventricle wall permeability increasing factor, or in combination with a locally or systemically co-administered agent.

In embodiments of the invention, TNR, a biologically active form of TNR, or an agonist of TNR, or a host cell expressing any of these, is administered by intraventricularly, intravenously, intraarterially, intracerebroventricularly, intraparenchymally, intrathecally, or intracranially.

Neural stem cells and their progeny can be induced to migrate in vivo by administering TNR, a biologically active fragment of TNR, or a TNR agonist to the host, alone or in combination with other agents in a pharmaceutical composition that will induce proliferation, differentiation, and survival of the cells. Pharmaceutical compositions include any substance that blocks the inhibitory influence and/or stimulates neural stem cells and stem cell progeny to migrate and/or survive. Such in vivo manipulation allows new cells to (i) endogenously or exogenously replace those lost due to injury or disease, thus obviating the need for transplanting foreign cells into a patient, or (ii) create a molecular microenvironment that rescues any damaged or injured tissue.

In embodiments of the invention, the neural stem cell or neural progenitor cell is derived from fetal brain, adult brain, neural cell culture, a neurosphere, tissue enclosed by dura mater, peripheral nerves, ganglia, pancreas, skin, muscle, adult bone marrow, umbilical cord tissue and umbilical cord blood.

The invention relates to the treatment of a “neurological disease, disorder, or damage,” which is a disease, damage, or disorder that results in the disturbance in the structure or function of the central pr peripheral nervous system resulting from developmental abnormality, disease, injury or toxin. Examples of neurological diseases or disorders include, but are not limited to, neurodegenerative disorders (e.g. associated with Parkinson's disease or Parkinsonian disorders, Alzheimer's disease, Huntington's disease, Shy-Drager Syndrome, Progressive Supranuclear Palsy, Lewy Body Disease or Amyotrophic Lateral Sclerosis); ischemic disorders (e.g. cerebral or spinal cord infarction and ischemia, stroke); traumas (e.g. caused by physical injury or surgery, and compression injuries; affective disorders (e.g. stress, depression and post-traumatic depression); neuropsychiatric disorders (e.g. schizophrenia or other psychoses, multiple sclerosis or epilepsy); and learning and memory disorders.

In other embodiments of the invention, the disease or disorder of the nervous system is selected from the group consisting of cancer-related brain/spinal cord injury or diseases or disorders of the nervous system, including, but not limited to, lissencephaly syndrome, depression, bipolar depression/disorder, anxiety syndromes/disorders, phobias, stress and related syndromes, cognitive function disorders, aggression, drug and alcohol abuse, obsessive compulsive behavior syndromes, seasonal mood disorder, borderline personality disorder, cerebral palsy, drug addictions, multi-infarct dementia, Lewy body dementia, age related/geriatric dementia, epilepsy and injury related to epilepsy, temporal lobe epilepsy, brain injury, trauma related brain/spinal cord injury, anti-cancer treatment related brain/spinal cord tissue injury, infection and inflammation related brain/spinal cord injury, environmental toxin related brain/spinal cord injury, autism, attention deficit disorders, narcolepsy, and sleep disorders.

In embodiments of the invention, the reference to disease, damage, or disorder of the nervous system is selected from the group consisting of neurodegenerative disorders, neural stem cell disorders, neural progenitor disorders, ischemic disorders, neurological traumas, affective disorders, neuropsychiatric disorders, degenerative diseases of the retina, retinal injury/trauma and learning and memory disorders.

This invention provides a method of treating a neurological disease, damage, or disorder comprising administering TNR, a biologically active form of TNR, or an agonist or antagonist of TNR that modulates neural stem cell or neural progenitor cell migration in vivo to a mammal. The term “mammal” refers to any animal classified as a mammal, including humans, cows, horses, dogs, sheep and cats. In a preferred embodiment, the mammal is a human.

The treatments encompassed by the invention may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned protein or peptide, analog, derivative, fragment, or homolog thereof; (ii) antibodies to an aforementioned protein or peptide; (iii) nucleic acids encoding an aforementioned protein or peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (e.g., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned protein or peptide by homologous recombination; or (v) modulators (e.g., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a protein or peptide of the invention) that alter the interaction between an aforementioned protein or peptide and its binding partner.

In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific therapeutic and whether its administration is indicated for treatment of the affected tissue. In various specific embodiments, in vitro assays may be performed with representative stem cells or newly differentiated cells involved in the patient's disorder, to determine if a given therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in the mammalian subject of the treatment. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.

A pharmaceutical composition useful as a therapeutic agent for the treatment of central or peripheral nervous system disorders is provided. For example, the composition includes TNR, a biologically active fragment of TNR, or an agonist of TNR, which can be administered alone or in combination with the systemic or local co-administration of one or more additional agents. Such agents include preservatives, ventricle wall permeability increasing factors, stem cell mitogens, survival factors, glial lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, and anti-pyrogenics. The pharmaceutical composition preferentially treats CNS diseases by stimulating cells (e.g., ependymal cells and subventricular zone cells) to migrate, targeting loci where cells are damaged or missing.

A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Solutions or suspensions used for administration can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™. (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., chimeric peptide) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

In one embodiment, the active TNR-related compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.

It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active TNR-related compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit form of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

Preferably the TNR, or fragment, derivative, or analog thereof, is formulated in a medium providing maximum stability and the least formulation-related side-effects. In addition to TNR, or fragment, derivative, or analog thereof, the composition of the invention will typically include one or more protein carrier, buffer, isotonic salt, and stabilizer.

In some instances, the TNR, a biologically active fragment of TNR, or an agonist of TNR can be administered by a surgical procedure implanting a catheter coupled to a pump device. The pump device can also be implanted or be extracorporally positioned. Administration of TNR, or a fragment, derivative, or analog thereof, can be in intermittent pulses or as a continuous infusion. Devices for injection to discrete areas of the brain are known in the art (see, e.g., U.S. Pat. Nos. 6,042,579; 5,832,932; and 4,692,147).

Compositions can be administered in any conventional form for administration of a protein. A composition can be administered in any manner known in the art in which it may either pass through or by-pass the blood-brain barrier. Methods for allowing factors to pass through the blood-brain barrier include minimizing the size of the factor, providing hydrophobic factors that may pass through more easily, conjugating the protein or other molecule to a carrier molecule that has a substantial permeability coefficient across the blood brain barrier (see, e.g., U.S. Pat. No. 5,670,477).

TNR, biologically active fragments of TNR, or TNR agonists, derivatives, and co-administered agents can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the agent and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the TNR-related active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions. Modifications can be made to the agents to affect solubility or clearance of the peptide. Peptidic molecules may also be synthesized with D-amino acids to increase resistance to enzymatic degradation. In some cases, the composition can be co-administered with one or more solubilizing agents, preservatives, and permeation enhancing agents.

For example, the composition can include a preservative or a carrier such as proteins, carbohydrates, and compounds to increase the density of the pharmaceutical composition. The composition can also include isotonic salts and redox-control agents.

In some embodiments, the composition administered includes TNR, or a fragment, derivative, or analog thereof, and one or more agents that increase the permeability of the ventricle wall, e.g. “ventricle wall permeability enhancers.” Such a composition can help an injected composition penetrate deeper than the ventricle wall. Examples of suitable ventricle wall permeability enhancers include, for example, liposomes, VEGF (vascular endothelial growth factor), IL-s, TNFα, polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid and derivatives thereof, EDTA, disodium EDTA, cholic acid and derivatives, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, urosdeoxycholic acid, saponins, glycyrrhizic acid, ammonium glycyrrhizide, decamethonium, decamethonium bromide, dodecyltrimethylammonium bromide, and dimethyl-β-cyclodextrin or other cyclodextrins.

The fact that neural stem cells are located in the tissues lining ventricles of mature brains offers several advantages for the modification and manipulation of these cells in vivo and the ultimate treatment of various neurological diseases, disorders, and injury that affect different regions of the CNS. Therapy for these diseases can be tailored accordingly so that stem cells surrounding ventricles near the affected region would be induced to migrate using the methods described herein.

The ventricular system is found in nearly all brain regions and thus allows easier access to the affected areas. In order to induce the stem cells to migrate in vivo by exposing them to a composition comprising TNR, a biologically active fragment of TNR, or an agonist of TNR, it is relatively easy to implant a device that administers the composition to the ventricle and, thus, to the neural stem cells. For example, a cannula attached to an osmotic pump may be used to deliver the composition. TNR should be delivered close to the ventricular system or alternatively between the ventricular system and the damaged tissue. Alternatively, the composition may be injected directly into the ventricles. The neural stem cell progeny can migrate into regions that have been damaged as a result of injury or disease. Furthermore, the close proximity of the ventricles to many brain regions would allow for the diffusion of a secreted neurological agent by the stem cells or their progeny.

In an additional embodiment, TNR, a biologically active fragment of TNR, or a TNR agonist is administered locally, as described above, in combination with an agent administered locally or systemically. Such agents include, for example, one or more stem cell mitogens, survival factors, differentiation factors, glial-lineage preventing agents, anti-apoptotic agents, anti-stress medications, neuroprotectants, and anti-pyrogenics, or any combination thereof.

The agent is administered systemically before, during, or after administration of the TNR, or fragment, derivative, or analog thereof. The locally administered agent can be administered before, during, or after TNR, or a fragment, derivative, or analog thereof, is administered.

For treatment of Huntington's Disease, Alzheimer's Disease, Parkinson's Disease, and other neurological disorders affecting primarily the forebrain, TNR, or a fragment, derivative, or analog thereof, alone or with an additional agent or agents can be delivered between the damaged or diseased area and the zone where neuroblasts are produced. For example, Parkinson's Disease is the result of low levels of dopamine in the brain, particularly the striatum. It is therefore advantageous to induce dopamine producing cells from either the patient's own cells or transplanted cells to migrate to the striatum, thus locally raising the levels of dopamine.

Normally the cell bodies of dopaminergic neurons are located in the substantia nigra and adjacent regions of the mesencephalon, with the axons projecting to the striatum. The methods and compositions of the invention provide an alternative to the use of drugs and the controversial use of large quantities of embryonic tissue for treatment of Parkinson's disease. Dopaminergic cells can be generated in the striatum by the administration of a composition comprising TNR, a biologically active fragment of TNR, or a TNR agonist.

For the treatment of MS and other demyelinating or hypomyelinating disorders, and for the treatment of Amyotrophic Lateral Sclerosis or other motor neuron diseases, TNR, a biologically active fragment of TNR, or a TNR agonist can be delivered either alone or with an additional agent or agents to the central canal.

In addition to treating CNS tissue immediately surrounding a ventricle, TNR, a biologically active fragment of TNR, or a TNR agonist, alone or with an additional agent or agents, can be administered to the lumbar cistern for circulation throughout the CNS.

In other aspects, neuroprotectants can also be co-administered systemically or locally before, during and/or after infusion of TNR, or a fragment, derivative, or analog thereof. Neuroprotectants include antioxidants (agents with reducing activity, e.g., selenium, vitamin E, vitamin C, glutathione, cysteine, flavinoids, quinolines, enzymes with reducing activity, etc), Ca-channel modulators, Na-channel modulators, glutamate receptor modulators, serotonin receptor agonists, phospholipids, unsaturated- and polyunsaturated fatty acids, estrogens and selective estrogen receptor modulators (SERMS), progestins, thyroid hormone and thyroid hormone-mimicking compounds, cyclosporin A and derivatives, thalidomide and derivatives, methylxanthines, MAO inhibitors; serotonin-, noradrenaline and dopamine uptake blockers; dopamine agonists, L-DOPA, nicotine and derivatives, and NO synthase modulators.

Certain components of the compositions of the invention may be pyrogenic following intravenous injection. Thus, in some aspects of the invention, antipyrogenic agents like cox2 inhibitors, indomethacin, salisylic acid derivatives and other general anti-inflammatory/anti-pyrogenic compounds can be systemically or locally administered before, during and/or after administration of a composition comprising TNR, a biologically active fragment of TNR, or a TNR agonist.

In another aspect of the invention, anti-apoptotic agents including caspase inhibitors and agents useful for antisense-modulation of apoptotic enzymes and factors can be administered before, during, or after administration of TNR, a biologically active fragment of TNR, or a TNR agonist.

Stress syndromes lower neurogenesis, therefore, in some aspects, it may be desirable to treat a subject with anti-stress medications such as, e.g., anti-glucocorticoids (e.g., RU486) and beta-blockers, administered systemically or locally before, during and/or after infusion of TNR, a biologically active fragment of TNR, or a TNR agonist.

Methods for preparing dosage forms are known, or will be apparent, to those skilled in this art.

The duration of treatment and time period of administration of TNR, or a fragment, derivative, or analog thereof, will also vary according to the size and condition of the patient, the severity of the illness and the specific composition and method being used.

The effectiveness of each of the foregoing methods for treating a patient with a CNS disease or disorder is assessed by any known standardized test for evaluating the disease.

In summary, it has now been demonstrated that (i) TNR is a key player in directing neuroblasts into their prospective target area, (ii) the level of TNR expression correlates strongly with olfactory sensory activity, and that (iii) grafting TNR-secreting cells into regions that do not receive progenitor neurons de-routes migrating neuroblasts to these areas. Thus, the activity-dependent recruitment of neuroblasts by TNR represents a fundamental mechanism through which neurogenesis in the adult OB is regulated and adapted to the level of sensory input. The TNR signaling pathway provides a novel approach for cell replacement therapies based on de-routing migrating cells.

Throughout this application, various publications are referenced in parentheses by author and year. Full citations for these references may be found at the end of the specification immediately preceding the sequence listing and the claims. The disclosure of these publications in their entireties are hereby incorporated by reference into this application to describe more fully the art to which this invention pertains.

The following examples are presented to demonstrate the methods of the present invention and to assist one of ordinary skill in using the same. The examples are not intended in any way to otherwise limit the scope of the disclosure.

EXAMPLE 1

Animals. Two- to four-month-old TNR-deficient mice (Weber et al., 1999) and age-matched wild-type littermates were derived from heterozygous parents with a mixed C57BL/6J×129Ola background. Animals were kept on a 12 hour light-dark cycle at constant temperature (22° C.) with food and water ad libitum. Unilateral olfactory deprivation was performed on three- to four-month-old C57BL/6J mice by cauterizing one nostril (Meisami, 1976). All experimental procedures were in accordance with the Society for Neuroscience and European Union guidelines, and were approved by our institutional animal care and utilization committees.

BrdU injections. The DNA synthesis marker 5-bromo-2′-deoxyuridine (BrdU; Sigma) was dissolved in a sterile solution of 0.9% NaCl and 1.75% NaOH (0.4 N). This solution was injected intraperitoneally at a concentration of 50 mg/kg of body weight. BrdU containing cells were detected by immunohistochemistry after different survival times: A single dose of BrdU was given two hours prior to killing the animal to assess proliferation, or four hours to assess both proliferation and initial stages of migration. Two injections of BrdU spaced by four hours were done two days before sacrificing the animals to evaluate proliferation and migration of neuroblasts. Finally, four injections repeated every two hours were administrated to animals 21 days before sacrifice to evaluate proliferation, migration and survival of newborn cells.

Immunohistochemistry. For all histological analyses requiring tissue fixation by perfusion, mice were deeply anesthetized with an overdose of sodium pentobarbital (100 mg/kg; Sanofi, Gentilly, France), and perfused intracardiacally with saline solution (0.9% NaCl) containing heparin (5×10³ units/ml) at 37° C., followed by 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3). The brains were dissected out and immersed overnight in the same fixative at 4° C. Immunohistochemistry was performed on 40 μm-thick free-floating coronal or sagittal sections cut with a vibrating microtome (VT1000S, Leica, Rueil-Malmaison, France) and collected in PBS. Sections were first incubated overnight at 4° C. with the following monoclonal antibodies: mouse anti-TNR (clone 619; ref. 40), mouse anti-PSA and mouse anti-NeuN (Chemicon, Temecula, Calif.), mouse anti-Ki67 (Novocastra, Newcastle, England), rabbit anti-GFAP (Dako, Trappes, France) and rat anti-BrdU (Accurate Scientific, Harlan Sera-Lab, Loughborough, England).

To obtain BrdU immunostaining, the sections were pretreated with 0.2% Triton X-100 for two hours, and the DNA was denaturated with 2N HCl for 30 min at 37° C. An overnight incubation with the anti-BrdU antibody at 4° C. was followed by a three-hour incubation at room temperature with biotinylated donkey anti-rat IgG antibodies, one hour in the avidin-biotin complex (ABC Kit, Vectastain Elite, Vector Laboratories, Burlingame, Calif.), and development with diaminobenzidine (DAB, 0.05%), to which 0.005% H₂O₂ was added. Double- and triple-labeling immunofluorescence was performed with the following fluorescent secondary antibodies: Alexa 568-labeled goat anti-rat IgG, Alexa 488-labeled goat anti-mouse IgG or IgM, and Cy5 anti-mouse IgG (Molecular Probes, Poortgebouw, Netherlands). Sections were analyzed using either a standard microscope (BX51; Olympus, Hamburg, Germany) for peroxidase staining or a Zeiss confocal microscope (Carl Zeiss S. A. S., Le Pecq, France) equipped with lasers Ar 488, HeNe1 543 and HeNe2 633, with LSM-510 software package for image acquisition and data analysis.

Terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL) staining was performed in 8 μm thick coronal sections of the OB to detect DNA fragmentation in situ. After deparaffinization and rehydration, the tissue was treated with 0.5% Triton X-100 for 10 min, followed by incubation in equilibrium buffer (Serological Corporation, Norcross, Calif.). Sections were then incubated for 1 hour in a humidified chamber at 37° C., with a solution containing terminal deoxynucleotidyl transferase and digoxigenin nucleotides (Serological Corporation). After vigorous washing, a peroxidase labeled anti-digoxigenin antibody (Serological Corporation) was added for 30 min at room temperature, and staining was revealed by DAB.

The forebrains of unilaterally occluded mice were embedded in gelatin and cut in 40 μm thick coronal sections. Sections containing both bulbs, thus ipsi- and contralateral to the occluded nostril, were immunostained for TNR and TNR immunoreactivity was quantified by laser confocal microscopy using identical acquisition parameters for both bulbs.

In situ hybridization. The fresh-frozen brains of sham and unilaterally odor-deprived mice were cut in 20 μm thick coronal slices. The sections containing control and occluded bulbs were thawed onto Superfrost Plus slides and stored at −80° C. until used. Hybridization was performed with the synthetic oligonucleotides (Eurogentec, Seraing, Belgium) 5′ AAG CCC CTC CTT CCT CCT CCA CAG TTT GTC TCT GAG CCC TTT CTG 3′ (SEQ ID NO: 3) complementary to nucleotides 720-764 of the mRNA encoding Mus musculus TNR (GenBank Accession No. NM-022312). The sequence of the probe was checked in a GenBank database search to exclude significant homology with other genes. The probe was labeled with [³³P]dATP (PerkinElmer, Mechelen, Germany) by using terminal deoxynucleotidyl transferase (Roche, Mannheim, Germany) reaction following the manufacturer's instructions. The sections were hybridized overnight at 42° C. in the hybridization mixture containing 50% formamide, 10% dextran sulfate, 4×SSC (1×SSC is 0.15M NaCl, 0.015M Na-citrate). Following hybridization, the sections were washed for 30 min in 1×SSC pre-warmed to 60° C., rinsed in 0.1×SSC and dehydrated in ascending concentration of ethanol. The digitalized autoradiograms were obtained by exposing sections in a β-imager (Biospace, Paris, France). This real-time imager provides rapid cartography of [³³P] labeling (in cpm/mm²) in tissue sections.

TNR-secreting cells. A 6.2 kb cDNA fragment containing nucleotides 1 to 4070 of the coding sequence of the 180 kD rat TNR protein was cloned into the XhoI site of the pcDNA3 vector (Invitrogen) for TNR expression under the control of the CMV promoter. For expression of the protein, the BHK cell line was transfected with 2 μg plasmid pcDNA3-TNR per well in a 6-well plate using the Lipofectamine kit (Invitrogen), following the manufacturer's instructions. Twenty four hours post-transfection TNR was detected by immunocytochemistry at the cell surface of the transfected cells, but not of the untransfected cells. Furthermore, culture supernatants were collected and analyzed for secretion of TNR by Western blotting. A specific immunoreactive band was seen at 180 kD in the supernatants of transfected, but not of non-transfected BHK cells.

SVZ explant cultures. Cultures of SVZ explants were prepared as previously described (Fuss et al., 1993). Briefly, brains from P7 mice were dissected out and immersed in ice-cold HBSS medium (Gibco, Cergy Pontoise, France). The brains were cut in 200 μm thick sections, and those containing SVZ were selected for further manipulations. Under a surgical microscope, the SVZ was dissected along the lateral wall of lateral ventricles and then cut into small pieces (100-200 μm in diameter) that were transferred to 70% Matrigel (BD Bioscience, Le Pont de Claix, France). After polymerization of Matrigel at 37° C. for 10 min, neurobasal medium containing B27 supplement, L-glutamine (0.5 mM) and penicillin/streptomycin (1:1000) (all from Gibco) was added. Cultures were maintained in a humidified, 5% CO₂, 37° C. incubator. In some experiments, SVZ explants were co-cultured with aggregates of control or TNR-transfected BHK cells. Aggregates of BHK cells were prepared under low serum conditions using a hanging-drop method (Fan and Tessier-Lavigne, 1994).

Grafting experiments. Control and TNR-expressing BHK cells were labeled with the PKH26 red fluorescent cell linker kit (Sigma) following the manufacturer's instructions resulting in the staining of about 90% of all cells. Cells were grafted to the part of the striatum neighboring the SVZ (from bregma: anterio-posterior=1.5; medio-lateral=1.0; dorso-ventral=2.6) and just above the horizontal limb of RMS (anterio-posterior=3.35; medio-lateral=0.82; and dorso-ventral=3.0) using a Kopf stereotaxic apparatus (Harvard Apparatus, Les Ulis, France). On the day of transplantation, BHK cells were resuspended by trypsinization and collected after centrifugation (10 min, 475 g). For transplantation, animals were anesthetized with a ketamine/xylazine mixture (Sigma) and approximately 2×10⁵ BHK cells in 0.3 μl of solution were injected over a time period of three minutes using a very thin glass electrode. The electrode was then left in place for an additional three minutes before being slowly withdrawn. Animals were killed four days later and the number of PSA-NCAM+ cells exiting the SVZ or RMS was counted in sagittal sections containing the grafts. The same sections were also processed for TNR immunolabeling.

Quantification and statistical analyses. All quantifications were performed blind to the experimental conditions. For analysis of cell migration distance in vitro, explants were examined using phase-contrast microscopy after 20 hours in culture. Migration distance was quantified by measuring the maximum distance that cells had moved away from the perimeter of each explant.

BrdU immunostained nuclei were quantified in every third 40 μm section along the entire SVZ-OB pathway. To assess the number of newborn neurons in the OB, BrdU+ nuclei, observed with 20× and 40× objectives, were numbered for the entire granule cell and glomerular layers. The numbers of BrdU+ profiles were then related to the surface of granule cell (including mitral cell and internal plexiform layers) and glomerular layers. For RMS and SVZ, the density of BrdU+ cells was evaluated by relating the number of BrdU+ cells to the surfaces occupied by these cells. To count the number of TUNEL+ cells in the granule cell layer and RMS_(OB), these areas were delineated manually on Methyl Green (Vector Laboratories, Burlingame, Calif.) counterstained sections. The percentage of BrdU/NeuN and BrdU/GFAP double immunostained cells were obtained by analyzing 3D reconstructed BrdU+ nuclei in the x-z and y-z orthogonal projections for the presence or absence of NeuN or GFAP.

The number of neuroblasts migrating towards the grafted BHK cells was quantified by counting the number of PSA-NCAM+ cells that had detached from the SVZ or RMS. In animals grafted with BHK cells secreting TNR, TNR-immunoreactive areas were as large as 100-400 μm in diameter. To assess the number of de-routed neuroblasts in BHK-injected mice, PSA-NCAM+ cells outside of their normal migratory pathway were counted in the 400 μm diameter area, calculated from the perimeter of the graft. Counting was done along the entire z axis, and data are presented as the total number of PSA-NCAM+ cells de-routed from the SVZ or the RMS.

To quantify the impact of sensory deprivation on TNR mRNA expression, the [³³P] activity (in cpm/mm²) of occluded bulb was related to that of control bulb of the same section. To assess downregulation of TNR at protein level, the mean fluorescent intensity (per mm²) of occluded bulb was related to that of control bulb of TNR immunostained sections.

All statistical comparisons between groups were made by using Student's t test.

EXAMPLE 2 Expression of TNR in the Adult OB

To examine the expression pattern of TNR in the adult mouse SVZ-OB system, immunofluorescence labeling was combined with confocal microscopy. At various magnifications, scanning through the successive sections from the SVZ to the OB (FIG. 3 a-c) revealed strong TNR-positive (TNR+) staining, which was restricted to the granule cell and internal plexiform layers of the OB (FIGS. 3 c and 3 d). The SVZ and RMS, identified using antibodies against the polysialylated form of the neural cell adhesion molecule (PSA-NCAM), a marker for immature neurons (FIGS. 3 a and 3 b), were always devoid of TNR labeling. No staining for TNR was observed in the OB of TNR-deficient mice. The TNR immunostaining pattern is consistent with previous in situ hybridization data showing that granule cells are the major source of TNR synthesis in the adult OB (Fuss, et al., 1993). The exclusive pattern of TNR expression in the deep layers of the OB surrounding the RMS, and not within it, suggests a potential role of TNR in recruiting newborn neurons to the adult OB.

EXAMPLE 3 Reduced Number of Newborn Cells in the OB of TNR-Deficient Mice

To investigate the potential role of TNR in bulbar neurogenesis, TNR-deficient mice were used. Adult mutant and wild-type mice were given four pulses of BrdU, a marker for DNA synthesis, and brains were processed for BrdU immunohistochemistry 21 days later. Most of the BrdU+ nuclei were found scattered throughout the granule cell layer (FIG. 4 a) and, to a lesser extent, in the glomerular layer (FIG. 4 c). The mean density of BrdU+ nuclei located in the granule cell layer was significantly lower in mutants than in control mice (241±16 versus 421±42 cells/mm², respectively, n=4 for each genotype, P<0.01; FIG. 4 b). A similar effect was also found in the glomerular layer (90±12 versus 148±2 cells/mm², P<0.01; FIG. 4 d).

To test whether the 40% reduction seen in TNR-deficient mice was accompanied with alterations in the fate of newborn cells, the proportion of cells double-labeled for BrdU and either the neuronal marker NeuN (FIG. 4 e) or the glial marker GFAP (FIG. 4 g) was determined. Orthogonal projections through 3D reconstructed BrdU+ cells revealed that, in both genotypes, about 80% of newborn cells were neurons (n=4; FIG. 4 f). Similarly, despite the very small number of BrdU+/GFAP+ cells (only approximately 1% of all BrdU+ cells), no difference was seen between genotypes (n=4; FIG. 4 h). These results demonstrate that the reduction in the density of BrdU+ cells was similar in the different layers of the mutant OB, but that the fate of newly generated cells remained unchanged.

EXAMPLE 4 Altered Radial Migration in TNR-Deficient Mice

The reduced number of newborn cells in the OB could result from decreased cell proliferation and rate of tangential migration, altered chain organization, distorted radial migration and/or reduced survival of newborn neurons. To assess proliferation, the number of mitotically active cells in the SVZ and the RMS four hours after BrdU injection was quantified. When compared with control animals, the distribution of BrdU+ cells in the SVZ-OB pathway was unchanged in TNR-deficient mice (FIG. 5 a). The densities of BrdU+ cells in the SVZ (FIGS. 5 b and d) and RMS (FIGS. 5 c and d) were undistinguishable between genotypes (2414±156 versus 2721±90 cells/mm² in the SVZ and 2992±221 versus 3298±138 cells/mm² in the RMS, for control and mutant mice, respectively; n=3, P>0.05).

To assess whether deficiency in TNR affects tangential migration, the cytoarchitecture of the SVZ and RMS was examined. The chains of neuroblasts visualized by PSA-NCAM immunostaining in whole-mount preparations of the SVZ were similar in mutant and control mice (FIG. 6 a). At both low and high magnifications, an extensive network of tangential pathways could readily be observed. Most of the chains in this network formed a longitudinal array that was not altered in mutant animals. Similarly, the organization of PSA-NCAM+ chains along the migratory pathway to the OB was the same in both genotypes (FIG. 6 b).

To characterize the distribution of newborn cells in these chains, animals received a BrdU injection and were killed two hours later. In both genotypes, double labeling for PSA-NCAM and BrdU revealed the presence of dividing precursors integrated in chains along the entire pathway (FIGS. 6 b and c), thus demonstrating that the organization of neuroblast chains is unaffected by the absence of TNR.

SVZ explants were then cultured on Matrigel to assess the rate of neuroblast migration. This technique has previously been adapted for the study tangential cell migration in vitro (Hack et al., 2002; Wichterle, et al., 1997; Chazal et al., 2000). When SVZ explants from P7 control and mutant mice were cultured for 20 hours, an extensive network of chains formed around the explants (FIG. 6 d). There was no difference in the general organization of the network of chains (FIGS. 6 d and e), and quantification of their length also did not reveal any significant difference (210±12 μm versus 209±11 μm, for control and mutant animals, respectively, 12 explants from four control animals and eight explants from three mutants, P>0.05; FIG. 4 f).

Altogether, these results demonstrate that TNR is not involved in proliferation and tangential migration of neuroblasts. This is consistent with our immunohistological observations that TNR is not detectable in the SVZ and RMS. By contrast, high expression of TNR in the adult OB might play a role either in recruiting neuroblasts from the RMS to the OB or in their survival within the OB.

To determine whether granule cells in the OB of mutant mice might be dying at a higher rate than in controls, TUNEL staining was performed to evaluate the level of apoptosis. The number of TUNEL+ cells in both granule cell layer and the RMS_(OB) were quantified (FIGS. 7 a and b). Numbers of TUNEL+ cells did not differ between genotypes (3.4±0.4 versus 3.3±0.4 cells/slice in the granule cell layer and 1.2±0.3 versus 1.7±0.5 in the RMS_(OB) of control and mutant mice, respectively; n=3, P>0.05; FIG. 7 b). The combined data suggest that the reduced density of BrdU+ cells in the mutant OB results from altered radial migration. If this were the case, the reduced density of newborn cells in the OB should be accompanied by an accumulation of neuroblasts in the RMS_(OB).

Next, an examination was made to determine whether BrdU+ cells would appear “trapped” in the RMS_(OB) of TNR-deficient animals. Animals were killed two days following BrdU injection, and BrdU+ cells were quantified throughout the entire SVZ-OB pathway (FIG. 7 d). Newborn cells accumulated exclusively in the RMS_(OB) of mutant mice (FIG. 7 c), but not in the RMS or the SVZ (FIG. 7 d), confirming that TNR does not affect proliferation and tangential migration. The accumulation of neuroblasts in the RMS_(OB) of TNR-deficient mice was highly significant, when compared to controls (3646±97 and 2470±214 cells/mm², respectively; n=4; P<0.01; FIGS. 5 d and g), and was accompanied by reduced number of BrdU+ cells migrating from the RMS_(OB) to the OB (FIGS. 7 e and f). The highest decrease was measured in the external plexiform layer (18±0.8 versus 29.4±4.7 BrdU+ cells/mm² for mutant and control mice, respectively; P<0.05) and in the glomerular layer (75.1±11.9 versus 104.7±15.3 BrdU+ cells/mm²; P<0.05; FIG. 7 e). A lesser, non-significant decrease was found in the granule cell layer (20.1±2.8 versus 24±2 BrdU+ cells/mm²; P>0.05).

To estimate whether excess of BrdU+ cells in the RMS_(OB) of TNR-deficient mice is due to the accumulation of non-migrated cells in that region, the changes in the number of BrdU+ cells in the RMS_(OB) and OB in TNR-deficient mice was compared. TNR-deficient mice had 30.1±7.7 more BrdU+ cells per slice in the RMS_(OB) (105.1±7.7 versus 75±7.1 cells/slice for TNR-deficient and control mice, respectively; P<0.05) and 20.8±9.4 less BrdU+ cells per slice in the OB, including glomerular, external plexiform and granule cells layers, (62.5±4 versus 83.3±9.4 cells/slice for TNR-deficient and control mice, respectively; P<0.05). Interestingly, the total number of BrdU+ cells counted in the OB and RMS_(OB) was not different in TNR-deficient as compared to control animals (167.6±10.5 versus 158.3±15.3 BrdU+ cells per slice for TNR-deficient and control mice, respectively; P>0.05). These results demonstrate that the excess of BrdU+ cells in the RMS_(OB) of TNR-deficient mice is due to the accumulation of non-migrating cells in that region.

Interestingly, in both genotypes, the density of BrdU+ cells in the glomerular layer was quite similar for 2 and 21 days of BrdU post-injection (compare with FIG. 4 d). This contrasts sharply with the density of BrdU+ cells counted in the granule cell layer, which increased 20-fold between 2 and 21 days post-injection (compare with FIG. 4 b). These results suggest that neuroblasts first migrate predominantly to the glomerular layer before populating the granule cell layer. Thus, this might explain why the density of newborn cells two days after BrdU injection was mainly decreased in the glomerular and external plexiform layers, but only slightly in the granule cell layer of TNR-deficient mice.

Since cell proliferation, tangential migration and cell death were not affected in TNR-deficient mice, the reduced density of newborn neurons in the OB and increased number of neuroblasts in the RMS_(OB) suggest that newborn progenitors are impeded in leaving the RMS_(OB). Thus, the kinetics of accumulation of newborn cells in the RMS_(OB) was tested. When animals were given a pulse of BrdU and sacrificed four hours later, the density of BrdU+ cells in the RMS_(OB) was higher in TNR-deficient mice than in the controls (129.2±11.7 versus 100.7±3 cells/mm²; P<0.05; n=5; FIG. 7 g). This increase was even higher two days after BrdU injection (FIG. 7 g). Indeed, when the data were expressed as the ratio of mutant to control BrdU+ cell densities in the RMS_(OB), the increase was significantly smaller for the four hour versus two day BrdU post-injection values (respectively, 1.3±0.09 versus 1.5±0.04, P<0.05; FIG. 7 h). These results strongly suggest that the absence of TNR leads to an accumulation of newborn cells in the RMS_(OB).

To rule out the possibility that elevated numbers of neuroblasts in the RMS_(OB) of TNR-deficient mice result from increased local proliferation of neuroblast precursors, two sets of experiments were performed. First, by injecting BrdU and sacrificing animals two hours later, dividing progenitors in the SVZ-OB pathway were specifically labeled. The number of BrdU+ cells in the RMS_(OB), stained with PSA-NCAM antibodies, was not different between genotypes (55.0±10.1 versus 49.5±8 cells/mm² for control and TNR-deficient mice, respectively; P>0.05; n=4; see FIG. 11), indicating similar local proliferation rates. In agreement, the number of cells marked by the endogenous cell division marker Ki67 (Tanapat, et al., 1999; Kee et al., 2002) was not different in the RMS_(OB) of control and mutant mice (85.5±50 versus 61.3±28.2 Ki67+ cells/mm²; P>0.05; n=4; see Supplementary FIG. 3 b). These results show that absence of TNR reduces the numbers of newborn bulbar neurons due to their accumulation in the RMS_(OB). This highlights the pivotal role for TNR in initiating radial migration.

EXAMPLE 5 TNR Promotes Individualization of Neuroblasts and Initiates their Radial Migration

Before invading the OB, neuroblasts halt their tangential migration, detach from their migrating chains and leave the RMS_(OB). To examine which of these steps might be regulated by TNR, both in vitro and in vivo approaches were combined. Inspection of PSA-NCAM+ staining at the interface between the RMS_(OB) and granule cell layer showed that most neuroblasts migrate individually in control animals, whereas many clustered in the mutants (FIG. 8 a). To assess the role of TNR in stopping tangential migration and detaching neuroblasts from chains, SVZ explants were co-cultured with TNR-expressing or control BHK cells (FIG. 8 b-d). When SVZ explants from P7 animals were co-cultured for 20 hours with BHK cells, an extensive network of neuroblasts migrated out of SVZ explants (FIGS. 8 c and d). Quantification of the number of individualized neuroblasts per SVZ explant revealed a significantly higher number of such cells in the presence of BHK cells secreting TNR (a 1.9-fold increase, P<0.001; FIG. 8 e). Noteworthy is the fact that the migration distance did not differ between control explants (248.5±7.1 μm; 24 explants from eight mice) and those exposed to TNR-secreting cells (260.9±6.5 μm; 29 explants from eight mice) (P=0.2; FIG. 8 f). These results indicate that the expression of TNR is instrumental for detaching neuroblasts from chains, but not for halting their tangential migration.

This in vitro assay, however, does not allow one to determine whether TNR also plays a role in the reorientation of tangentially migrating neuroblasts as seen in vivo in the core of the OB. To examine whether TNR is necessary and sufficient to re-route tangentially migrating neuroblasts, TNR was introduced into forebrain regions that are neither populated by progenitor cells nor express TNR (FIG. 9 a). TNR-expressing or control BHK cells pre-stained with PKH26 (red labeling in FIGS. 9 b and c) were grafted into the striatum (FIG. 9 b) or just above the horizontal limb of the RMS (hIRMS) (FIG. 9 c). While animals receiving control cells showed unaltered migration (upper panels in FIGS. 9 b and c; n=8), all mice grafted with transfected cells (n=7) had neuroblasts (green labeling in FIGS. 9 b and c) entering the TNR-containing area (blue staining in lower panels of FIGS. 9 b and c). Ectopic expression of TNR yielded a four to six fold increase in the number of neuroblasts migrating out of the SVZ and hIRMS (24.5±6.2 versus 86.7±19.0 and 15.3±10.5 versus 91.9±16.0 for control and TNR-secreting cells injected, respectively, into the striatum and close to the hIRMS; P<0.005; FIGS. 9 e and g). Interestingly, while 28.8±5.8% and 35.5±9.3% of neuroblasts that migrated out of SVZ and hIRMS, respectively, were detached from chains (FIGS. 9 d and f, arrows), many of the de-routed neuroblasts were still assemble in the chains (FIGS. 9 d and f, arrowheads). These results demonstrate that TNR not only promotes detachment of neuroblasts from chains, but also plays an important role in the reorientation of tangentially migrating neuroblasts.

EXAMPLE 6 Sensory Input Regulates the Level of TNR Expression in the OB

These results revealed that TNR was not only required, but also sufficient to initiate radial migration in the adult forebrain. It was thus decided to investigate whether this important function is regulated in an activity-dependent manner. Since the OB is the first central relay that receives direct inputs from sensory neurons, unilateral odor deprivation was used to test whether expression of TNR is sensitive to the level of sensory activity. Unilateral sensory deprivation resulted in the small, but statistically significant, decrease in TNR mRNA level in the ipsilateral bulb as soon as 1-2 days following nostril occlusion and which reached a maximum at 4-30 days following nostril occlusion (FIGS. 10 a and b). Interestingly, the reduction of TNR mRNA level was reversible, since re-opening of the nostril for five days following 20 days of occlusion resulted in the upregulation of TNR mRNA that reached the level of control bulb (FIG. 10 b). Concomitantly, the expression level of TNR protein was assessed following 20 days of odor deprivation. It was found that unilateral nostril occlusion also downregulated by 27±6% the protein expression in the GCL (FIGS. 8 c and d; n=5). These results indicate that TNR expression is indeed regulated by an activity-dependent mechanism.

To elucidate whether this activity-dependent regulation of TNR expression could have a functional implication in the recruitment of newly generated cells to the OB, the density of BrdU+ cells in the RMS_(OB) of control and occluded bulbs was inspected, two days following BrdU injection. Similar to results obtained from TNR-deficient mice, downregulation of TNR expression by unilateral odor deprivation for 30 days produced an accumulation of neuroblasts in the RMS_(OB) of occluded as compared to the control bulbs (4023.9±209.9 versus 3258.5±228.3 cells/mm² for odor-deprived and control bulbs, respectively; P<0.05; n=5; FIGS. 10 e and f). These results suggest that regulation of TNR expression by sensory input plays a key role in the recruitment of newborn neurons to the OB. Importantly, the accumulation of neuroblasts in the RMS_(OB) was less pronounced in the occluded animals as compared to the TNR-deficient mice (123.5±6.4% versus 147.5±4.1%, respectively; P<0.05), showing the correlation between the level of TNR expression in the OB and the degree of neuroblasts accumulation in the RMS_(OB).

REFERENCES

The entire disclosures of each of the following publications are relied upon and incorporated by reference herein:

-   1. Alvarez-Buylla, A. & Garcia-Verdugo, J. M. Neurogenesis in adult     subventricular zone. J. Neurosci. 22, 629-634 (2002). -   2. Arvidsson, A., Collin, T., Kirik, D., Kokaia, Z. & Lindvall, O.     Neuronal replacement from endogenous precursors in the adult brain     after stroke. Nat. Med. 8, 963-970 (2002). -   3. Ausubel et al., (Eds.) In: Current Protocols in Molecular     Biology. J. Wiley and Sons, New York, N.Y. (1998). -   4. Barany, et al, Intl. J. Peptide Protein Res. 30: 705-739 (1987). -   5. Bodasnsky, ed. Peptide Chemistry, A Practical Textbook,     Springer-Verlag (1988). -   6. Boudreau, N. & Bissell, M. J. Extracellular matrix signaling:     integration of form and function in normal and malignant cells.     Curr. Opin. Cell Biol. 10, 640-646 (1998). -   7. Bruckner, G. et al. Postnatal development of perineuronal nets in     wild-type mice and in a mutant deficient in tenascin-R. J. Comp.     Neurol. 428, 616-629 (2000). -   8. Brunjes, P. C. Unilateral naris closure and olfactory system     development. Brain Res. Brain Res. Rev. 19, 146-160 (1994). -   9. Carleton, A., Petreanu, L. T., Lansford, R., Alvarez-Buylla, A. &     Lledo, P. M. Becoming a new neuron in the adult olfactory bulb. Nat.     Neurosci. 6, 507-518 (2003). -   10. Chazal, G., Durbec, P., Jankovski, A., Rougon, G. & Cremer, H.     Consequences of neural cell adhesion molecule deficiency on cell     migration in the rostral migratory stream of the mouse. J. Neurosci.     20, 1446-1457 (2000). -   11. Chen et al., PNAS 91:3054-3057 (1994). -   12. Cummings, D. M. & Brunjes, P. C. The effects of variable periods     of functional deprivation on olfactory bulb development in rats.     Exp. Neurol. 148, 360-366 (1997). -   13. Cummings, D. M., Henning, H. E. & Brunjes, P. C. Olfactory bulb     recovery after early sensory deprivation. J. Neurosci. 17, 7433-7440     (1997). -   14. Fan, C. M. & Tessier-Lavigne, M. Patterning of mammalian somites     by surface ectoderm and notochord: evidence for sclerotome induction     by a hedgehog homolog. Cell 79, 1175-1186 (1994). -   15. Frazier, L. L. & Brunjes, P. C. Unilateral odor deprivation:     early postnatal changes in olfactory bulb cell density and     number. J. Comp. Neurol. 269, 355-370 (1998). -   16. Fuss, B., Wintergerst, E. S., Bartsch, U. & Schachner, M.     Molecular characterization and in situ mRNA localization of the     neural recognition molecule J1-160/180: a modular structure similar     to tenascin. J. Cell Biol. 120, 1237-1249 (1993). -   17. Hack, I., Bancila, M., Loulier, K., Carroll, P. & Cremer, H.     Reelin is a detachment signal in tangential chain-migration during     postnatal neurogenesis. Nat. Neurosci. 5, 939-945 (2002). -   18. Henegar, J. R. & Maruniak, J. A. Quantification of the effects     of long-term unilateral naris closure on the olfactory bulbs of     adult mice. Brain Res. 568, 230-234 (1991). -   19. Ike et al., Nucl. Acids Res. 11:477 (1983). -   20. Itakura et al., Annu Rev Biochem 53:323 (1984a). -   21. Itakura et al., Science 198:1056 (1984b). -   22. Jones, F. S. & Jones, P. L. The tenascin family of ECM     glycoproteins: structure, function, and regulation during embryonic     development and tissue remodeling. Dev. Dyn. 218, 235-259 (2000). -   23. Kaiser, et al, Science 243: 187-198 (1989). -   24. Kaufman et al. EMBO J 6: 187-195 (1987). -   25. Kee, N., Sivalingam, S., Boonstra, R. & Wojtowicz, J. M. The     utility of Ki-67 and BrdU as proliferative markers of adult     neurogenesis. J. Neurosci. Methods 115, 97-105 (2002). -   26. Kennedy, T. E. & Tessier-Lavigne, M. Guidance and induction of     branch formation in developing axons by target-derived diffusible     factors. Curr. Opin. Neurobiol. 5, 83-90 (1995). -   27. Kent, Ann. Rev. Biochem. 57:957-989 (1988). -   28. Komuro, H. & Rakic, P. Modulation of neuronal migration by NMDA     receptors. Science 260, 95-97 (1993). -   29. Luskin, M. B. Restricted proliferation and migration of     postnatally generated neurons derived from the forebrain     subventricular zone. Neuron 11, 173-189 (1993). -   30. Magavi, S. S., Leavitt, B. R. & Macklis, J. D. Induction of     neurogenesis in the neocortex of adult mice. Nature 405, 951-955     (2000). -   31. Meisami, E. Effects of olfactory deprivation on postnatal growth     of the rat olfactory bulb utilizing a new method for production of     neonatal unilateral anosmia. Brain Res. 107, 437-444 (1976). -   32. Merrifield, Science 232: 241-247 (1986). -   33. Milev, P. et al. High affinity binding and overlapping     localization of neurocan and phosphacan/protein-tyrosine     phosphatase-zeta/beta with tenascin-R, amphoterin, and the     heparin-binding growth-associated molecule. J. Biol. Chem. 273,     6998-7005 (1998). -   34. Morganti, M. C., Taylor, J., Pesheva, P. & Schachner, M.     Oligodendrocyte-derived J1-160/180 extracellular matrix     glycoproteins are adhesive or repulsive depending on the partner     cell type and time of interaction. Exp Neurol. 109, :98-110 (1990). -   35. Murase, S. & Horwitz, A. F. Deleted in colorectal carcinoma and     differentially expressed integrins mediate the directional migration     of neural precursors in the rostral migratory stream. J. Neurosci.     22, 3568-3579 (2002). -   36. Nakatomi, H. et al. Regeneration of hippocampal pyramidal     neurons after ischemic brain injury by recruitment of endogenous     neural progenitors. Cell 110, 429-441 (2002). -   37. Narang, Tetrahedron 39:3 (1983). -   38. Nikonenko, A., Schmidt, S., Skibo, G., Bruckner, G. and     Schachner, M. Tenascin-R-deficient mice show structural alterations     of symmetric perisomatic synapses in the CA1 region of the     hippocampus. J Comp Neurol. 456, 338-349 (2003). -   39. Pesheva, P., Gennarini, G., Goridis, C. & Schachner, M. The     F3/11 cell adhesion molecule mediates the repulsion of neurons by     the extracellular matrix glycoprotein J1-160/180. Neuron 10, 69-82     (1993). -   40. Pesheva, P. & Probstmeier, R. The yin and yang of tenascin-R in     CNS development and pathology. Prog. Neurobiol. 61, 465-493 (2000). -   41. Probstmeier, R., Michels, M., Franz, T., Chan, B. M. &     Pesheva, P. Tenascin-R interferes with integrin-dependent     oligodendrocyte precursor cell adhesion by a ganglioside-mediated     signalling mechanism. Eur. J. Neurosci. 11, 2474-2488 (1999). -   42. Rochefort, C., Gheusi, G., Vincent, J. D. & Lledo, P. M.     Enriched odor exposure increases the number of newborn neurons in     the adult olfactory bulb and improves odor memory. J. Neurosci. 22,     2679-2689 (2002). -   43. Saghatelyan, A. K. et al. Reduced perisomatic inhibition,     increased excitatory transmission, and impaired long-term     potentiation in mice deficient for the extracellular matrix     glycoprotein tenascin-R. Mol. Cell. Neurosci. 17, 226-240 (2001). -   44. Saghatelyan, A. et al. Recognition molecule associated     carbohydrate inhibits postsynaptic GABAb receptors: a mechanism for     homeostatic regulation of GABA release in perisomatic synapses. Mol.     Cell. Neurosci. (in press) (2003). -   45. Sambrook, et al., Molecular Cloning: A Laboratory Manual, 2nd     ed., (Cold Spring Harbor Laboratory Press; Cold Spring Harbor, N.Y.)     (1990). -   46. Seed, Nature 329:840 (1987). -   47. Srinivasan, J., Schachner, M. & Catterall, W. A. Interaction of     voltage-gated sodium channels with the extracellular matrix     molecules tenascin-C and tenascin-R. Proc. Natl. Acad. Sci. USA 95,     15753-15757 (1998). -   48. Svendsen, C. N. & Sofroniew, M. V. Do central nervous system     neurons require target-derived neurotrophic support for survival     throughout adult life and aging? Perspect. Dev. Neurobiol. 3,     133-142 (1996). -   49. Tanapat, P., Hastings, N. B., Reeves, A. J. & Gould, E. Estrogen     stimulates a transient increase in the number of new neurons in the     dentate gyrus of the adult female rat. J. Neurosci. 19, 5792-5801     (1999). -   50. Thomas, L. B., Gates, M. A. & Steindler, D. A. Young neurons     from the adult subependymal zone proliferate and migrate along an     astrocyte, extracellular matrix-rich pathway. Glia 17, 1-14 (1996). -   51. Weber, P. et al. Mice deficient for tenascin-R display     alterations of the extracellular matrix and decreased axonal     conduction velocities in the CNS. J. Neurosci. 19, 4245-4262 (1999). -   52. Wichterle, H., Garcia-Verdugo, J. M. & Alvarez-Buylla, A. Direct     evidence for homotypic, glia-independent neuronal migration. Neuron     18, 779-791 (1997). -   53. Xiao, Z. C. et al. Isolation of a tenascin-R binding protein     from mouse brain membranes. A phosphacan-related chondroitin sulfate     proteoglycan. J. Biol. Chem. 272, 32092-32101 (1997). -   54. Xiao, Z. C. et al. Defasciculation of neurites is mediated by     tenascin-R and its neuronal receptor F3/11. J. Neurosci. Res. 52,     390-404 (1998). -   55. Xiao, Z. C. et al. Tenascin-R is a functional modulator of     sodium channel beta subunits. J. Bio. Chem. 274, 26511-26517 (1999). 

1-26. (canceled)
 27. A pharmaceutical composition for treating a neurological disease or neurological damage in a mammal in vivo, wherein the composition comprises tenascin-R (TNR); and a pharmaceutically acceptable carrier; wherein the TNR is in an amount sufficient to induce migration of neuronal progenitor cells to a diseased or damaged area of the mammal's brain to replace neural cells lost due to the neurological disease or neurological damage or to revive surviving damaged neural cells.
 28. A pharmaceutical composition for treating a neurological disease or neurological damage in a mammal in vivo, wherein the composition comprises tenascin-R (TNR); at least one compound that enhances permeability of a ventricle wall of a ventricle in the brain of the mammal in an amount sufficient to allow the TNR to penetrate into the mammal's brain; and a pharmaceutically acceptable carrier; wherein the TNR is in an amount sufficient to induce migration of neuronal progenitor cells to a diseased or damaged area of the mammal's brain to replace neural cells lost due to the neurological disease or neurological damage or to revive surviving damaged neural cells.
 29. A pharmaceutical composition for treating a neurological disease or neurological damage in a mammal in vivo, wherein the composition comprises tenascin-R (TNR); at least one compound selected from liposomes, VEGF (vascular endothelial growth factor), interleukins, TNFα (tumor necrosis factor alpha), polyoxyethylene, polyoxyethylene ethers of fatty acids, sorbitan monooleate, sorbitan monolaurate, polyoxyethylene monolaurate, polyoxyethylene sorbitan monolaurate, fusidic acid, EDTA, disodium EDTA, cholic acid, deoxycholic acid, glycocholic acid, glycodeoxycholic acid, taurocholic acid, taurodeoxycholic acid, sodium cholate, sodium glycocholate, glycocholate, sodium deoxycholate, sodium taurocholate, sodium glycodeoxycholate, sodium taurodeoxycholate, chenodeoxycholic acid, urosdeoxycholic acid, saponins, glycyrrhizic acid, ammonium glycyrrhizide, decamethonium, decamethonium bromide, dodecyltrimethylammonium bromide, and dimethyl-β-cyclodextrin, in an amount sufficient to allow the TNR to penetrate into the mammal's brain; and a pharmaceutically acceptable carrier; wherein the TNR is in an amount sufficient to induce migration of neuronal progenitor cells to a diseased or damaged area of the mammal's brain to replace neural cells lost due to the neurological disease or neurological damage or to revive surviving damaged neural cells.
 30. The pharmaceutical composition of claim 27, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.001 ng/kg to 10 mg/kg in a volume of 0.0001 milliliters to 10 milliliters.
 31. The pharmaceutical composition of claim 30, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.01 ng/kg to 5 mg/kg in a volume of 0.0001 milliliters to 10 milliliters.
 32. The pharmaceutical composition of claim 31, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.1 ng/kg to 1 mg/kg in a volume of 0.0001 milliliters to 10 milliliters.
 33. The pharmaceutical composition of claim 32, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.1 ng/kg to 1 μg/kg, in a volume of 0.0001 milliliters to 10 milliliters.
 34. The pharmaceutical composition of claim 27, wherein the mammal is human.
 35. The pharmaceutical composition of claim 27, wherein the mammal is a cow, a horse, a dog, a sheep, a cat, or a mouse.
 36. The pharmaceutical composition of claim 27, wherein the neurological disease is chosen from Parkinson's disease, Parkinsonian disorders, Alzheimer's disease, Huntington's disease, Shy-Drager Syndrome, Progressive Supranuclear Palsy, Lewy Body Disease, Amyotrophic Lateral Sclerosis, cerebral infarction or ischemia, stroke, stress, depression, post-traumatic depression, schizophrenia, dementia, multiple sclerosis, epilepsy, autism, attention deficit disorders, and narcolepsy.
 37. The pharmaceutical composition of claim 27, wherein the neurological damage is chosen from trauma caused by physical injury to the brain, trauma caused by brain surgery, compression injuries of the brain, and cancer-related brain injury.
 38. The pharmaceutical composition of claim 27, further comprising an antipyrogenic agent in an amount sufficient to reduce fever in the mammal.
 39. The pharmaceutical composition of claim 38, wherein the antipyrogenic agent is selected from cox2 inhibitors, indomethacin, and salisylic acid.
 40. The pharmaceutical composition of claim 27, further comprising a host cell that secretes TNR.
 41. The pharmaceutical composition of claim 27, wherein the TNR is produced by a host cell present in the composition.
 42. The pharmaceutical composition of claim 40 or claim 41, wherein the host cell is selected from a bacterium, a fungus, and a mammalian cell.
 43. The pharmaceutical composition of claim 42, wherein the bacterium is E. coli.
 44. The pharmaceutical composition of claim 42, wherein the mammalian cell is selected from CHO cells (Chinese hamster ovary cells), BHK cells (baby hamster kidney cells), and COS cells.
 45. The pharmaceutical composition of claim 44, wherein the mammalian cell is a BHK cell.
 46. A pharmaceutical composition for treating a neurological disease or neurological damage in a mammal in vivo, wherein the composition comprises tenascin-R (TNR); at least one antipyrogenic agent in an amount sufficient to reduce fever in the mammal; and a pharmaceutically acceptable carrier; wherein the TNR is in amount sufficient to induce migration of neuronal progenitor cells to a diseased or damaged area of the mammal's brain to replace neural cells lost due to the neurological disease or neurological damage or to revive surviving damaged neural cells.
 47. A pharmaceutical composition for treating a neurological disease or neurological damage in a mammal in vivo, wherein the composition comprises tenascin-R (TNR); at least one compound selected from cox2 inhibitors, indomethacin, and salisylic acid, in an amount sufficient to reduce fever in the mammal; and a pharmaceutically acceptable carrier; wherein the TNR is in amount sufficient to induce migration of neuronal progenitor cells to a diseased or damaged area of the mammal's brain to replace neural cells lost due to the neurological disease or neurological damage or to revive surviving damaged neural cells.
 48. The pharmaceutical composition of claim 46, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.001 ng/kg to 10 mg/kg in a volume of 0.0001 milliliters to 10 milliliters.
 49. The pharmaceutical composition of claim 48, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.01 ng/kg to 5 mg/kg in a volume of 0.0001 milliliters to 10 milliliters.
 50. The pharmaceutical composition of claim 49, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.1 ng/kg to 1 mg/kg in a volume of 0.0001 milliliters to 10 milliliters.
 51. The pharmaceutical composition of claim 5Q, wherein the TNR is present in the composition in an amount to confer a daily dose range of 0.1 ng/kg to 1 μg/kg, in a volume of 0.0001 milliliters to 10 milliliters.
 52. The pharmaceutical composition of claim 46, wherein the mammal is human.
 53. The pharmaceutical composition of claim 46, wherein the mammal is a cow, a horse, a dog, a sheep, a cat, or a mouse.
 54. The pharmaceutical composition of claim 46, wherein the neurological disease is chosen from Parkinson's disease, Parkinsonian disorders, Alzheimer's disease, Huntington's disease, Shy-Drager Syndrome, Progressive Supranuclear Palsy, Lewy Body Disease, Amyotrophic Lateral Sclerosis, cerebral infarction or ischemia, stroke, stress, depression, post-traumatic depression, schizophrenia, dementia, multiple sclerosis, epilepsy, autism, attention deficit disorders, and narcolepsy.
 55. The pharmaceutical composition of claim 46, wherein the neurological damage is chosen from trauma caused by physical injury to the brain, trauma caused by brain surgery, compression injuries of the brain, and cancer-related brain injury.
 56. The pharmaceutical composition of claim 46, further comprising a host cell that secretes TNR.
 57. The pharmaceutical composition of claim 46, wherein the TNR is produced by a host cell present in the composition.
 58. The pharmaceutical composition of claim 56 or claim 57, wherein the host cell is selected from a bacterium, a fungus, and a mammalian cell.
 59. The pharmaceutical composition of claim 58, wherein the bacterium is E. coli.
 60. The pharmaceutical composition of claim 58, wherein the mammalian cell is selected from CHO cells (Chinese hamster ovary cells), BHK cells (baby hamster kidney cells), and COS cells.
 61. The pharmaceutical composition of claim 60, wherein the mammalian cell is a BHK cell.
 62. The pharmaceutical composition of any of claims 27, 28, 29, 46, or 47, wherein the TNR is chosen from the 180 kD, 220 kD, 200 kD, 280 kD, and 160 kD forms of TNR.
 63. The pharmaceutical composition of any of claims 27, 28, 29, 46, or 47, wherein the TNR amino acid sequence has at least 95% identity with SEQ ID NO:2.
 64. The pharmaceutical composition of claim 63, wherein the TNR amino acid sequence of SEQ ID NO:2 contains at least one conservative amino acid substitution.
 65. The pharmaceutical composition of claim 64, wherein the conservative amino acid substitution is a nonpolar amino acid chosen from alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.
 66. The pharmaceutical composition of claim 64, wherein the conservative amino acid substitution is a polar neutral amino acid chosen from glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine.
 67. The pharmaceutical composition of claim 64, wherein the conservative amino acid substitution is a positively charged amino acid chosen from arginine, lysine, and histidine.
 68. The pharmaceutical composition of claim 64, wherein the conservative amino acid substitution is a negatively charged amino acid chosen from aspartic acid and glutamic acid. 